Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001437749-26-005892

CEO and President sold 7,100 shares at an average $16.02 ($113,728)

  • CEO and President acquired 7,100 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Stengone Carmine N. · CEO and President

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2026-02-24 Exercise or conversion : show line 1 in the form 10b5-1 +4,400 $1.26 $5,544 19,354 D
2026-02-24 Sale : show line 2 in the form 10b5-1 −4,400 $16.02 $70,486 14,954 D
2026-02-25 Exercise or conversion : show line 3 in the form 10b5-1 +2,700 $1.26 $3,402 17,654 D
2026-02-25 Sale : show line 4 in the form 10b5-1 −2,700 $16.02 $43,242 14,954 D
Open-market sales · 7,100 sh · avg $16.02 · $113,728

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-02-24 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) −4,400 123,617 D
2026-02-25 Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (right to buy) −2,700 120,917 D
Loading xslF345X05/rdgdoc.xml…